•  
  •  
 

Abstract

The novel coronavirus disease (COVID-19) spread rapidly across all continents. However, data on all COVID-19 signs and symptoms are inadequate, Patients with COVID-19 may be more susceptible to fungal infections. Mucormycosis is an uncommon and often fatal fungal disease characterized via vascular invasion by hyphae leading to thrombosis and necrosis. Covid recovered patients with co morbidities like as diabetes or kidney disease, heart failure, or cancer are more likely to get black fungal infection. The signs of this infection are similar to those of Covid-19 and common flu, If the infection is neglected or mistreated, it can spread from the nose to the eyes and brain, resulting in life-threatening complications. Prompt diagnosis, therapy initiation, as well as considering the limitations of quick development COVID-19 therapeutic recommendations were already essential to increasing survival of patients.This study aimed to explain the correlation between Covid 19 & Mucormycosis.

References

  1. Clancy CJ, Schwartz IS, Kula B, Nguyen MH. Bacterial superinfections among persons with coronavirus disease 2019: a comprehensive review of data from postmortem studies. InOpen Forum Infect Dis 2021 Mar;8(3):ofab065. https://doi.org/10.1093/ofid/ofab065. US: Oxford University Press.
  2. Rocha IC, Hasan MM, Goyal S, Patel T, Jain S, Ghosh A, et al. COVID-19 and mucormycosis syndemic: double health threat to a collapsing healthcare systemin India. TropMed IntHealth 2021 Sep;26(9):1016e8. https://doi.org/10.1111/tmi.13641.
  3. Xia ZK, Wang WL, Yang RY. Slowly progressive cutaneous, rhinofacial, and pulmonary mucormycosis caused by Mucor irregularis in an immunocompetent woman. Clin Infect Dis 2013 Apr 1;56(7):993e5. https://doi.org/10.1093/cid/cis1045.
  4. Sen M, Honavar SG, Sharma N, Sachdev MS. COVID-19 and eye: a review of ophthalmic manifestations of COVID-19. Indian J Ophthalmol 2021 Mar;69(3):488. https://doi.org/10.4103/ijo.IJO_297_21.
  5. Alekseyev K, Didenko L, Chaudhry B. Rhinocerebral mucormycosis and COVID-19 pneumonia. J Med Cases 2021 Mar;12(3):85. https://doi.org/10.14740/jmc3637.
  6. Richardson M. The ecology of the Zygomycetes and its impact on environmental exposure. Clin Microbiol Infect 2009 Oct;15:2e9. https://doi.org/10.1111/j.1469-0691.2009.02972.x.
  7. Kanamori H, Rutala WA, Sickbert-Bennett EE, Weber DJ. Review of fungal outbreaks and infection prevention in healthcare settings during construction and renovation. Clin Infect Dis 2015 Aug 1;61(3):433e44. https://doi.org/10.1093/cid/civ297.
  8. Islam MT, Parvin M, Nasir M. Mucormycosis (the black fungus) during COVID-19 pandemic: growing concerns of immunosuppressive therapy and uncontrolled diabetes mellitus. Int J Commun Med Publ Health 2021 Aug;8(8):4067. https://doi.org/10.18203/2394-6040.ijcmph20212759.
  9. Bhat I, Beg MA, Athar F. A contemporary intimidation for COVID-19 patients coinfected with mucormycosis in India. J Bacteriol Mycol Open Access 2021;9(2):69e71. https://doi.org/10.15406/jbmoa.2021.09.00298.
  10. Muthu V, Kumar M, Paul RA, Zohmangaihi D, Choudhary H, Rudramurthy SM, et al. Is there an association between zinc and COVID-19eassociated mucormycosis? Results of an experimental and clinical study. Mycoses 2021 Oct;64(10):1291e7. https://doi.org/10.1111/myc.13365.
  11. Gokulshankar S, Mohanty BK. COVID-19 and black fungus. Asian J Med Health Sci 2021 Jun;4(1):138.
  12. Mahalaxmi I, Kaavya J, Mohana Devi S, Balachandar V. COVID-19 and olfactory dysfunction: a possible associative approach towards neurodegenerative diseases. J Cell Physiol 2021 Feb;236(2):763e70. https://doi.org/10.1002/jcp.29937.
  13. John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi 2021 Apr 15;7(4):298. https://doi.org/10.3390/jof7040298.
  14. Khatri A, Chang KM, Berlinrut I, Wallach F. Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipientecase report and review of literature. J Med Mycol 2021 Jun 1;31(2):101125.https://doi.org/10.1016/j.mycmed. 2021.101125.
  15. Zurl C, Hoenigl M, Schulz E, Hatzl S, Gorkiewicz G, Krause R, et al. Autopsy proven pulmonary mucormycosis due to Rhizopus microsporus in a critically ill COVID-19 patient with underlying hematological malignancy. J Fungi 2021 Jan 27;7(2):88.https://doi.org/10.3390/jof7020088.
  16. Maini A, Tomar G, Khanna D, Kini Y, Mehta H,Bhagyasree V.Sino-orbital mucormycosis in a COVID-19 patient: a case report.Int J Surg Case Rep 2021 May 1;82:105957.https://doi.org/10.1016/j. ijscr. 2021. 105957.
  17. Vishnupriya M,Naveenkumar M, Manjima K, Sooryasree NV, Saranya T, Ramya S, et al.Post-COVID pulmonary fibrosis: therapeutic efficacy using with mesenchymal stem cellseHow the lung heals.Eur Rev Med Pharmacol Sci 2021 Mar 1;25(6):2748e51.https://doi.org/10.26355/eurrev_202103_25438.
  18. Renu K, Subramaniam MD, Chakraborty R, Myakala H,Iyer M,Bharathi G, et al.The role of Interleukin-4 in COVID-19 associated male infertilityeA hypothesis.J Reprod Immunol 2020 Nov 1;142:103213.https://doi.org/10. 1016/j.jri. 2020. 103213.
  19. Jayaramayya K,Mahalaxmi I, Subramaniam MD, Raj N, Dayem AA, Lim KM, et al.Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cellderived exosomes for COVID-19 treatment.BMB Reports 2020 Aug 8;53(8):400.https://doi.org/10. 5483/BMBRep. 2020. 53. 8. 121.
  20. Balachandar V,Mahalaxmi I, Subramaniam M, Kaavya J, Kumar NS, Laldinmawii G, et al.Follow-up studies in COVID-19 recovered patients-is it mandatory?Sci Total Environ 2020 Aug 10;139021:729.https://doi.org/10. 1016/j.scitotenv. 2020. 139021.
  21. Johnson AK, Ghazarian Z, Cendrowski KD, Persichino JG. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. Med Mycol Case Rep 2021 Jun 1;32:64e7. https://doi.org/10.1016/j.mmcr.2021.03.006.
  22. Dallalzadeh LO, Ozzello DJ, Liu CY, Kikkawa DO, Korn BS. Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19. Orbit 2021 Mar 25:1e4. https://doi.org/10.1080/01676830.2021.
  23. Moorthy A, Gaikwad R, Krishna S, Hegde R, Tripathi KK, Kale PG, et al. SARS-CoV-2, uncontrolled diabetes and corticosteroidsdan unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multicentric analysis. J Maxillofac Oral Surg 2021 Sep;20(3):418e25. https://doi.org/10.1007/s12663-021-01532-1.
  24. Sarkar S, Gokhale T, Choudhury SS, Deb AK. COVID-19 and orbital mucormycosis. Indian J Ophthalmol 2021 Apr 1;69(4):1002. https://doi.org/10.4103/ijo.IJO_3763_20.
  25. Kanwar A, Jordan A, Olewiler S, Wehberg K, Cortes M, Jackson BR. A fatal case of Rhizopus azygosporus pneumonia following COVID-19. J Fungi 2021 Feb 28;174(3):7. https://doi.org/10.3390/jof7030174.
  26. Suryanarayanan TS, Shaanker U. COVID-19 and black fungus: what is mucormycosis. Health Sci 2021.
  27. Iyer M, Tiwari S, Renu K, Pasha MY, Pandit S, Singh B, et al. Environmental survival of SARS-CoV-2ea solid waste perspective. Environ Res 2021 Jun 1;197:111015. https://doi.org/10.1016/j.envres.2021.111015.
  28. Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: a case report. Eur J Ophthalmol 2021 Apr 10. https://doi.org/10.1177/11206721211009450.
  29. Alshahawey MG, El-Housseiny GS, Elsayed NS, Alshahrani MY, Wakeel LM, Aboshanab KM. New insights on mucormycosis and its association with the COVID-19 pandemic. Fut Sci OA 2022 Feb;8(2):FSO772. https://doi.org/10.3390/biomed2020017.
  30. Basile K, Halliday C, Kok J, Chen SC. Fungal infections other than invasive Aspergillosis in COVID-19 patients. J Fungi 2022 Jan 6;8(1):58. https://doi.org/10.3390/jof8010058.
  31. Girdhar D, Manocha E. A comprehensive review on the management of COVID-19-associated mucormycosis (CAM): the new basics. BioMed 2022 Apr 12;2(2):181e98. https://doi.org/10.3390/biomed2020017.
  32. Revannavar SM, Supriya PS, Samaga L, Vineeth V. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? BMJ Case Reports CP 2021 Apr 1;14(4). https://doi.org/10.1136/bcr-2021-241663.
  33. Agnihotri AK, Vij M, Aruoma OI, Yagnik VD, Bahorun T, Villamil ME, et al. The double trouble: COVID-19 associated mucormycosis a focused review and future perspectives. Glob J Med Pharmaceut Biomed Update 2021 Jul 3;16. https://doi.org/10.25259/GJMPBU_4_2021.
  34. Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia 2020 Aug;185(4):599e606. https://doi.org/10.1007/s11046-020-00462-9.
  35. Pandiar D, Kumar NS, Anand R, Kamboj M, Narwal A, Shameena PM. Does COVID 19 generate a milieu for propagation of mucormycosis? Med Hypotheses 2021 Jul 1;152:110613. https://doi.org/10.1016/j.mehy.2021.110613.
  36. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol 2010 Sep;47(3):193e9.https://doi.org/10.1007/s00592-009-0109-4.
  37. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 2020 Feb 24;12(1):1e5.https://doi.org/10.1038/s41368-020-0074-x.
  38. Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020 Jul 1;180(7):934e43. https://doi.org/10.1001/jamainternmed.2020.0994.
  39. Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol 2018 Apr 1;56(suppl_1):S93e101. https://doi.org/10.1093/mmy/myx101.
  40. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SC, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 2019 Dec 1;19(12):e405e21. https://doi.org/10.1016/S1473-3099(19)30312-3.
  41. Ally MT, Jenkins IH, Gupta V. Mucormycosis: more than meets the eye! Am J Med 2019 Sep 1;132(9):1044e6. https://doi.org/10.1016/j.amjmed.2019.04.007.
  42. Kunnumakkara AB, Rana V, Parama D, Banik K, Girisa S, Henamayee S, et al. COVID-19, cytokines, inflammation, and spices: how are they related? Life Sci 2021 Nov 1;284:119201. https://doi.org/10.1016/j.lfs.2021.119201.
  43. Vellingiri B, Jayaramayya K, Iyer M, Narayanasamy A, Govindasamy V, Giridharan B, et al. COVID-19: a promising cure for the global panic. Sci Total Environ 2020 Jul 10;725:138277. https://doi.org/10.1016/j.scitotenv.2020.138277.
  44. Sravani T, Uppin SG, Uppin MS, Sundaram C. Rhinocerebral mucormycosis: pathology revisited with emphasis on perineural spread. Neurol India 2014 Jul 1;62(4):383. https://doi.org/10.4103/0028-3886.141252.
  45. Binder U, Maurer E, Lass-Fl€orl C. Mucormycosisefrom the pathogens to the disease. Clin Microbiol Infect 2014 Jun;20:60e6. https://doi.org/10.1111/1469-0691.12566.
  46. Mekonnen ZK, Ashraf DC, Jankowski T, Grob SR, Vagefi MR, Kersten RC, et al. Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. Ophthalmic Plast Reconstr Surg 2021 Mar;37(2):e40. https://doi.org/10.1097/IOP.0000000000001889.
  47. Kinoshita M, Sato K, Vellingiri B, Green SJ, Tanaka M. Inverse association between hypertension treatment and COVID-19 prevalence in Japan. Int J Infect Dis 2021 Jul 1;108:517e21. https://doi.org/10.1016/j.ijid.2021.05.071.

Download
COinS